1. Pink Sheet

Definitive Data Hopes Keep Santhera's Duchenne Drug Alive in UK Despite EMA No

 
• By Neena Brizmohun

The European Medicines Agency rejected Santhera’s Raxone as a treatment for Duchenne muscular dystrophy but the prospect of definitive data supporting the new indication means idebenone will still be available to patients in the UK under the early access scheme for promising new medicines. 

Duchenne
Santhera's DMD treatment remains on the UK early access scheme • Source: Shutterstock

The UK drug regulator has decided not to drop Santhera Pharmaceuticals’s drug Raxone (idebenone) from its early access to medicines scheme (EAMS) as a treatment for Duchenne muscular dystrophy, despite the European Medicines Agency saying the product should not be approved.

The EAMS designation for Raxone was granted last June and allows Santhera to make the drug available to patients in the UK for the unlicensed DMD indication

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet